CUPR (Cuprina Holdings (Cayman)) Research & Development: $0.18 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CUPR Cuprina Holdings (Cayman) Ltd CUPR
10 GF Score
Price $4.09
! 6 Warning Signs
View Full Analysis

What is Cuprina Holdings (Cayman) Research & Development?

Cuprina Holdings (Cayman) CUPR -5.54% 10 Research & Development is $0.18 Mil as of Dec. 2025. GuruFocus rates CUPR with a GF Score™ of 10/100. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cuprina Holdings (Cayman)'s Research & Development for the six months ended in Dec. 2025 was $0.08 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $0.18 Mil.

Cuprina Holdings (Cayman)  (NAS:CUPR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cuprina Holdings (Cayman) Research & Development Related Terms

Cuprina Holdings (Cayman) Research & Development Historical Data

* Premium members only.

The historical data trend for Cuprina Holdings (Cayman)'s Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cuprina Holdings (Cayman) Research & Development Chart

Cuprina Holdings (Cayman) Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
0.21 0.22 0.13 0.18 0.18

Cuprina Holdings (Cayman) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only 0.07 0.05 0.13 0.10 0.08
CUPR
10GF Score
Cuprina Holdings (Cayman) Ltd CUPR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cuprina Holdings (Cayman) Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.18 Mil mean?
Cuprina Holdings (Cayman) (CUPR) has a Research & Development of $0.18 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Cuprina Holdings (Cayman) and its competitors.
Is Cuprina Holdings (Cayman)'s Research & Development too high?
Cuprina Holdings (Cayman)'s current Research & Development is $0.18 Mil. Overall, Cuprina Holdings (Cayman) has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Cuprina Holdings (Cayman)'s Research & Development compare to BNGO and UEEC?
Cuprina Holdings (Cayman)'s Research & Development of $0.18 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cuprina Holdings (Cayman) and its competitors. Cuprina Holdings (Cayman)'s current Research & Development is $0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cuprina Holdings (Cayman) stock overvalued right now?
Cuprina Holdings (Cayman) (CUPR) has a current Research & Development of $0.18 Mil. The current Research & Development is $0.18 Mil. Cuprina Holdings (Cayman)'s overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cuprina Holdings (Cayman) (CUPR), the current Research & Development is $0.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cuprina Holdings (Cayman) Business Description

Address c/o Blk 1090 Lower Delta Road No. 06-08, Singapore, SGP, 169201
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.
10GF Score

Get the complete analysis for CUPR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.09
Price